Completed study

Official Study Title
A randomized clinical trial for enhanced trained immune responses through Bacillus Calmette-Guérin vaccination to prevent infections by COVID-19

Brief Description
ACTIVATE-II is a randomized clinical trial aiming to investigate if the developing concept of trained immunity i.e. the memory of the innate immune system coming after vaccination exists in humans and may lead to protection from COVID-19.

Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 11 sites in Greece
Actual enrolment: 301 participants Identifier: NCT04414267
EudraCT number: 2020-002448-21
National Organization for Medicines Approval: IS045-20
National Ethics Committee Approval: 52/20

Study Start: June 2020
Study Completion: May 2021

Condition/Disease studied: COVID-19; Virus Diseases; Corona Virus Infection; Coronary Heart Disease; Chronic Obstructive Pulmonary Disease
Keywords: COVID-19; SARS-CoV-2; Vaccination; Bacillus Calmette-Guérin vaccination

Related publications